Targeting C3/C3aR After Status Epilepticus: Promise, Pharmacology, and Unresolved Mechanisms
Epilepsy Currents · 14.11.2026
DOI: 10.1177/15357597261495864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy Currents, online erschienen am 14.11.2026. Verfasst von Nicholas H Varvel. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bindarit attenuates brain injury and neuroinflammation in status epilepticus by disrupting C3/C3aR signaling and modulating microglia-astrocyte interactions. Chen J, Hu Y, Xie J, Zhou H, Yang T, Yu M, Wu J, Pan S, Huang K. Cell Commun Signal . 2026;24(1):322. doi: 10.1186/s12964-026-02876-2. PMID: 41975466; PMCID: PMC13217937. Cell Communication and Signaling.
Background
Status epilepticus (SE) is a life-threatening neurological emergency with high mortality, often leading to acute cerebral edema and chronic cognitive impairment. Its pathology involves both immune and vascular dysfunction. The complement C3/C3a receptor (C3/C3aR) signaling pathway has recently emerged as a key regulator of immune activation and blood-brain barrier (BBB) permeability. This study investigates whether bindarit, a potent anti-inflammatory drug, mitigates SE-induced brain injury through modulation of the C3/C3aR pathway.
Methods
SE modeling mice were randomized to receive daily bindarit or vehicle. To explore underlying mechanisms, C3aR antagonist (C3aRA) and recombinant C3a were used in additional groups. Post-SE brain injuries were assessed, including survival, memory performance, histopathology, brain edema, BBB integrity, neurovascular inflammation, microglia-astrocyte interactions, and microglial synaptic engulfment.
Results
We found that bindarit treatment improved survival and memory, reduced histological damage, alleviated brain edema, preserved BBB integrity, and attenuated endothelial inflammation in SE mice. It promoted a shift in microglia from a pro-inflammatory to an anti-inflammatory-associated features, reversed pathological microglia astrocyte crosstalk, limited synaptic elimination, and restored microglial morphology. Mechanistically, bindarit Inhibited neurotoxic astrocyte-derived C3 production and reduced C3aR expression in both microglia and endothelial cells. C3aRA produced comparable protective effects, whereas co-administration of C3a partially negated bindarit's benefits.
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Nicholas H Varvel
Zitieren
APA
Varvel, N. H. (2026). Targeting C3/C3aR After Status Epilepticus: Promise, Pharmacology, and Unresolved Mechanisms. Epilepsy Currents. https://doi.org/10.1177/15357597261495864
Vancouver
Varvel NH. Targeting C3/C3aR After Status Epilepticus: Promise, Pharmacology, and Unresolved Mechanisms. Epilepsy Currents. 2026. doi:10.1177/15357597261495864
BibTeX
@article{Varvel2026,
author = {Varvel, Nicholas H},
title = {Targeting C3/C3aR After Status Epilepticus: Promise, Pharmacology, and Unresolved Mechanisms},
journal = {Epilepsy Currents},
year = {2026},
doi = {10.1177/15357597261495864}
}
EUVIMED